NasdaqGM:TVTXBiotechs
Travere Therapeutics (TVTX) Faces FILSPARI Delay and Legal Scrutiny Is Execution Risk Repricing Ahead?
In recent days, Travere Therapeutics disclosed that the FDA classified additional data for its FILSPARI sNDA as a major amendment, extending the review timeline and setting a new PDUFA action date of April 13, 2026, while multiple law firms announced investigations into potential securities law violations related to the company’s disclosures.
This combination of a lengthened regulatory path for a key rare-disease therapy and parallel securities investigations adds an extra layer of...